239 related articles for article (PubMed ID: 35121889)
1. Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma.
Ma W; Wang Y; Zhang R; Yang F; Zhang D; Huang M; Zhang L; Dorsey JF; Binder ZA; O'Rourke DM; Fraietta JA; Gong Y; Fan Y
Nat Cancer; 2021 Jan; 2(1):83-97. PubMed ID: 35121889
[TBL] [Abstract][Full Text] [Related]
2. PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy.
Zhang D; Li AM; Hu G; Huang M; Yang F; Zhang L; Wellen KE; Xu X; Conn CS; Zou W; Kahn M; Rhoades SD; Weljie AM; Fuchs SY; Amankulor N; Yoshor D; Ye J; Koumenis C; Gong Y; Fan Y
Cell Metab; 2023 Mar; 35(3):517-534.e8. PubMed ID: 36804058
[TBL] [Abstract][Full Text] [Related]
3. PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration.
Su S; You S; Wang Y; Tamukong P; Quist MJ; Grasso CS; Kim HL
Cancer Lett; 2023 Feb; 555():216034. PubMed ID: 36509363
[TBL] [Abstract][Full Text] [Related]
4. c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma.
Huang M; Liu T; Ma P; Mitteer RA; Zhang Z; Kim HJ; Yeo E; Zhang D; Cai P; Li C; Zhang L; Zhao B; Roccograndi L; O'Rourke DM; Dahmane N; Gong Y; Koumenis C; Fan Y
J Clin Invest; 2016 May; 126(5):1801-14. PubMed ID: 27043280
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-485 inhibits malignant biological behaviour of glioblastoma cells by directly targeting PAK4.
Mao K; Lei D; Zhang H; You C
Int J Oncol; 2017 Nov; 51(5):1521-1532. PubMed ID: 29048626
[TBL] [Abstract][Full Text] [Related]
6. The role of PAK4 in the immune system and its potential implication in cancer immunotherapy.
Naїja A; Merhi M; Inchakalody V; Fernandes Q; Mestiri S; Prabhu KS; Uddin S; Dermime S
Cell Immunol; 2021 Sep; 367():104408. PubMed ID: 34246086
[TBL] [Abstract][Full Text] [Related]
7. PAK4 inhibition improves PD-1 blockade immunotherapy.
Abril-Rodriguez G; Torrejon DY; Liu W; Zaretsky JM; Nowicki TS; Tsoi J; Puig-Saus C; Baselga-Carretero I; Medina E; Quist MJ; Garcia AJ; Senapedis W; Baloglu E; Kalbasi A; Cheung-Lau G; Berent-Maoz B; Comin-Anduix B; Hu-Lieskovan S; Wang CY; Grasso CS; Ribas A
Nat Cancer; 2020; 1(1):46-58. PubMed ID: 34368780
[TBL] [Abstract][Full Text] [Related]
8. A novel interaction of PAK4 with PPARγ to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma.
Kesanakurti D; Maddirela D; Banasavadi-Siddegowda YK; Lai TH; Qamri Z; Jacob NK; Sampath D; Mohanam S; Kaur B; Puduvalli VK
Oncogene; 2017 Sep; 36(37):5309-5320. PubMed ID: 28534509
[TBL] [Abstract][Full Text] [Related]
9. Vascular Microenvironment, Tumor Immunity and Immunotherapy.
Lamplugh Z; Fan Y
Front Immunol; 2021; 12():811485. PubMed ID: 34987525
[TBL] [Abstract][Full Text] [Related]
10. The p21-activated kinase 4-Slug transcription factor axis promotes epithelial-mesenchymal transition and worsens prognosis in prostate cancer.
Park JJ; Park MH; Oh EH; Soung NK; Lee SJ; Jung JK; Lee OJ; Yun SJ; Kim WJ; Shin EY; Kim EG
Oncogene; 2018 Sep; 37(38):5147-5159. PubMed ID: 29849120
[TBL] [Abstract][Full Text] [Related]
11. PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma.
Liu T; Ma W; Xu H; Huang M; Zhang D; He Z; Zhang L; Brem S; O'Rourke DM; Gong Y; Mou Y; Zhang Z; Fan Y
Nat Commun; 2018 Aug; 9(1):3439. PubMed ID: 30150753
[TBL] [Abstract][Full Text] [Related]
12. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
[TBL] [Abstract][Full Text] [Related]
13. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
14. An immunosuppressive vascular niche drives macrophage polarization and immunotherapy resistance in glioblastoma.
Yang F; Akhtar MN; Zhang D; El-Mayta R; Shin J; Dorsey JF; Zhang L; Xu X; Guo W; Bagley SJ; Fuchs SY; Koumenis C; Lathia JD; Mitchell MJ; Gong Y; Fan Y
Sci Adv; 2024 Mar; 10(9):eadj4678. PubMed ID: 38416830
[TBL] [Abstract][Full Text] [Related]
15. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.
Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L
Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553
[TBL] [Abstract][Full Text] [Related]
16. Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response.
Xu S; Ma B; Jian Y; Yao C; Wang Z; Fan Y; Ma J; Chen Y; Feng X; An J; Chen J; Wang K; Xie H; Gao Y; Li L
EBioMedicine; 2024 Jun; 104():105162. PubMed ID: 38810561
[TBL] [Abstract][Full Text] [Related]
17. Targeting of p21-Activated Kinase 4 Radiosensitizes Glioblastoma Cells via Impaired DNA Repair.
Blankenstein LJ; Cordes N; Kunz-Schughart LA; Vehlow A
Cells; 2022 Jul; 11(14):. PubMed ID: 35883575
[TBL] [Abstract][Full Text] [Related]
18. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
19. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
20. Drug discovery targeting p21-activated kinase 4 (PAK4): a patent review.
Wang H; Song P; Gao Y; Shen L; Xu H; Wang J; Cheng M
Expert Opin Ther Pat; 2021 Nov; 31(11):977-987. PubMed ID: 34369844
[No Abstract] [Full Text] [Related]
[Next] [New Search]
